Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Tremelimumab in Metastatic HER2 Negative Breast Cancer
NCT02536794Phase 2Completed
- Sponsor
- Northwestern University
- Start
- Jan 2016
- Primary completion
- Feb 2020
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab and tremelimumab in breast cancer, sponsored by Northwestern University. Primary endpoint: Overall Response Rate. Started Jan 2016; status: completed.
02
Drugs
durvalumabtremelimumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02536794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02536794.